Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025Blood AdvancesOpen Access

Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMichaël LoschiMVMarie‐Charlotte VillyJGJacques‐Emmanuel Galimard

Discussion

Loading...

Member takes

Overview

Observational analysis reports 2-year leukemia-free survival of 68.6% in DDX41 mutated patients, indicating potential for late relapse.

Key Points

  • 2-year leukemia-free survival in DDX41 mutated patients was 68.6%, but late relapse remains a concern.
  • Non-relapse mortality in DDX41 mutated patients was recorded at 21.1%, highlighting treatment challenges.
  • PD patients showed no significant differences in survival rates compared to wild-type, suggesting similar treatment responses.
  • Incidence of donor cell leukemia was observed, emphasizing the need for cautious donor selection based on DDX41 status.

Cite This Study

Loschi et al. (2025) studied this question.

synapsesocial.com/papers/68d413ff713b0b5dfea61fc7https://doi.org/10.1182/bloodadvances.2025017084
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality2025
  2. 2Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  3. 3DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre2025
  4. 4Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits2025
  5. 5Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study2025